BRIEF published on 03/31/2026 at 08:05, 13 days 9 hours ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 13 days 9 hours ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 13 days 10 hours ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 25 days 7 hours ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
BRIEF published on 03/19/2026 at 10:19, 25 days 7 hours ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
PRESS RELEASE published on 03/19/2026 at 10:14, 25 days 7 hours ago Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026 Pentixapharm Holding AG to release 2025 financial report on March 26, 2026. CEO and CBO to discuss fiscal year results and strategic priorities in conference call Conference Call Strategic Priorities Clinical Trials Pentixapharm Holding AG 2025 Financial Report
BRIEF published on 02/25/2026 at 08:05, 1 month 16 days ago Pentixapharm Advances CXCR4-Based Hemato-Oncology Program with FDA Approval FDA Approval Hemato-oncology CXCR4-targeted Radiotheranostic Stem Cell Transplant
BRIEF published on 02/25/2026 at 08:05, 1 month 16 days ago Pentixapharm fait progresser son programme d'hémato-oncologie basé sur le CXCR4 grâce à l'approbation de la FDA Greffe De Cellules Souches Approbation De La FDA Radiothéranostique Hémato-oncologie Ciblage De CXCR4
PRESS RELEASE published on 02/25/2026 at 08:00, 1 month 16 days ago Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program Pentixapharm receives FDA approval for dual theranostic INDs in hemato-oncology program, targeting AML and MM with CXCR4-directed radiotherapy FDA Approval Pentixapharm CXCR4 Dual Theranostic Hemato-oncology Program
BRIEF published on 02/05/2026 at 08:35, 2 months 8 days ago Pentixapharm's PENTIXAFOR Shows Promise in Non-Invasive Diagnosis of Primary Aldosteronism Primary Aldosteronism PentixaFor Phase 2 Data Non-invasive Diagnostic PET/CT Imaging
Published on 04/13/2026 at 16:00, 2 hours ago Norsemont To Participate in The Inaugural Swiss Mining Institute Conference in Panama City April 15-16
Published on 04/13/2026 at 15:10, 2 hours 50 minutes ago Datavault AI Announces Upcoming Listing of Meme Coin Portfolio and Institutional RWA Token Suite on the Biconomy Exchange
Published on 04/13/2026 at 14:30, 3 hours 30 minutes ago Kestrel Gold - Appoints New Director and CEO and Grants Stock Options
Published on 04/13/2026 at 14:30, 3 hours 30 minutes ago TripSitter Completes Debt Settlement and Announces Financing
Published on 04/13/2026 at 17:45, 15 minutes ago Readcrest Capital to build 100 apartments in Schwerin - Construction is expected to begin in the first quarter of 2027
Published on 04/13/2026 at 17:35, 25 minutes ago GEVELOT S.A.: Déclaration hebdomadaire de rachat d'actions 13 04 2026
Published on 04/13/2026 at 17:35, 25 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 04/13/2026 (French only)
Published on 04/13/2026 at 17:11, 49 minutes ago Edison issues report on Aberdeen Asian Income Fund (AAIF)
Published on 04/13/2026 at 17:04, 56 minutes ago Edison issues report on Scottish Mortgage Investment Trust (SMT)
Published on 04/13/2026 at 17:42, 18 minutes ago Aéroports de Paris SA - Actions et droits de vote au 31 mars 2026
Published on 04/13/2026 at 17:42, 18 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 March 2026
Published on 04/13/2026 at 17:35, 25 minutes ago Disclosure of transactions in own shares from April 1 to April 10, 2026
